Trial reportNature medicine2023
Signaling-specific inhibition of the CB
Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
17.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, Update 2018-2023: Current Status, Best Practices, and Opportunities for Advancing the Science.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53Pooled it
- Psychotomimetic Cannabinoid Hyperlocomotion Involves GSK-3β Signaling at Striatopallidal Neurons in Male Mice.Biological psychiatry global open science · 2026Article
- Human behavioral pharmacology of cannabis: Insights on cannabis use disorder.Preventive medicine · 2026Article
- Effects of acute THC challenge on behavior and neuroinflammation in HIV-1 Tg26 mice vary based on HIV status, chronic THC history, and sex.Brain, behavior, and immunity · 2026Article
- A Male Mouse Model of WIN 55,212-2 Self-Administration to Study Cannabinoid Addiction.Bio-protocol · 2026Article
- Therapeutic potential of acidic cannabinoids: an update.Journal of cannabis research · 2026Review
- Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.Current topics in behavioral neurosciences · 2026Review
- Structural Perspectives on Biased Allostery of GPCR Signaling.Handbook of experimental pharmacology · 2026Review
- Unravelling the multifaceted actions of neurosteroids: Machine learning and in vitro screening for novel target discovery.British journal of pharmacology · 2025Article
- Integrating endocannabinoid signaling, CCK interneurons, and hippocampal circuit dynamics in behaving animals.Neuron · 2025Review
- Single cell resolution of neurosteroidogenesis in the murine brain: intermediary biosynthesis.The Journal of endocrinology · 2025Article
- Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.Acta pharmacologica Sinica · 2025Review
- New directions in neurosteroid therapeutics in neuropsychiatry.Neuroscience and biobehavioral reviews · 2025Review
- Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacology, biochemistry, and behavior · 2025Review
- ABHD6 loss-of-function in mesoaccumbens postsynaptic but not presynaptic neurons prevents diet-induced obesity in male mice.Nature communications · 2024Article
- Review
- Cannabis use disorder: from neurobiology to treatment.The Journal of clinical investigation · 2024Review
- The influence of drug class on reward in substance use disorders.Pharmacology, biochemistry, and behavior · 2024Review
- Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
Corrections and comments
- Commented on by
Authors and funding
38 authors at 11 institutions in 7 countries.
Margaret Haney *Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
Monique Vallée *University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Sandy Fabre *Aelis Farma, Bordeaux, France.ORCID 0000-0002-8850-0901
Stephanie Collins ReedDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.ORCID 0000-0002-6269-308X
Marion ZaneseAelis Farma, Bordeaux, France.ORCID 0000-0002-0521-517X
Ghislaine CampistronAelis Farma, Bordeaux, France.
Caroline A AroutDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
Richard W FoltinDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
Ziva D CooperDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.ORCID 0000-0001-8001-2332
Tonisha Kearney-RamosDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
Mathilde MetnaAelis Farma, Bordeaux, France.
Zuzana JustinovaBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.ORCID 0000-0001-5793-7484
Charles SchindlerBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.ORCID 0000-0001-7911-9116
Etienne Hebert-ChatelainDepartment of Biology, University of Moncton, Moncton, NB, Canada.
Luigi BellocchioUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Adeline CathalaUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Andrea BariAelis Farma, Bordeaux, France.
Roman SerratAelis Farma, Bordeaux, France.
David B FinlayDepartment of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Filippo CaraciUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.ORCID 0000-0002-9867-6054
Bastien RedonUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Elena Martín-GarcíaLaboratory of Neuropharmacology, Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-4487-3028
Arnau Busquets-GarciaUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.ORCID 0000-0002-7100-8873
Isabelle MatiasUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Frances R LevinDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
François-Xavier FelpinNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Nicolas SimonAix Marseille Univ, APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, Marseille, France.
Daniela CotaUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.ORCID 0000-0002-6909-2156
Umberto SpampinatoUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
Rafael MaldonadoLaboratory of Neuropharmacology, Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-4359-8773
Yavin ShahamBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.ORCID 0000-0002-8242-3319
Michelle GlassDepartment of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Lars Lykke ThomsenAelis Farma, Bordeaux, France.ORCID 0000-0001-5788-6867
Helle MengelAelis Farma, Bordeaux, France.
Giovanni MarsicanoUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.ORCID 0000-0003-3804-1951
Stéphanie MonlezunAelis Farma, Bordeaux, France.
Jean-Michel RevestUniversity of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.ORCID 0000-0001-6459-0888
Pier Vincenzo PiazzaAelis Farma, Bordeaux, France. pv.piazza@aelisfarma.com.ORCID 0000-0002-6101-9691
Université de Bordeaux · FRColumbia University · USNational Institutes of Health · USUniversitat Pompeu Fabra · ESUniversity of Otago · NZCentre National de la Recherche Scientifique · FRExelis (United States) · USInserm · FRUniversité de Moncton · CAUniversity of California, Los Angeles · USUniversity of Geneva · CH
Funding
Training and Education CoreU54DA037842 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI LEVIN, FRANCES RUDNICK · 2014 to 2018
$14.3MNon-Metabolized Pregnenolone Derivatives:New Treatment for Cannabis Use DisorderR01DA038875 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HANEY, MARGARET · 2016 to 2017
$3.1MNIDA NIH HHS R01 DA038875NIDA NIH HHS U54 DA037842
Abstract
Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB
Indexed as
CannabisHallucinogensMarijuana AbuseSubstance Withdrawal SyndromeAnimalsDouble-Blind MethodDronabinolHumansMiceDronabinolHallucinogens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.